Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $32.25 Consensus Target Price from Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have earned a consensus rating of “Buy” from the ten brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $32.2513.

A number of analysts recently weighed in on BCAX shares. Piper Sandler started coverage on shares of Bicara Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $36.00 price target for the company. Wall Street Zen cut shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Wells Fargo & Company upgraded shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price target for the company in a research note on Friday, May 23rd. HC Wainwright decreased their price target on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. Finally, Wedbush reiterated an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, August 12th.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC grew its position in Bicara Therapeutics by 28.7% in the 4th quarter. Millennium Management LLC now owns 385,406 shares of the company’s stock valued at $6,714,000 after buying an additional 85,847 shares during the last quarter. Northern Trust Corp purchased a new position in Bicara Therapeutics in the 4th quarter valued at $2,771,000. Deutsche Bank AG purchased a new position in Bicara Therapeutics in the 4th quarter valued at $1,959,000. Bank of America Corp DE grew its position in Bicara Therapeutics by 278.4% in the 4th quarter. Bank of America Corp DE now owns 33,677 shares of the company’s stock valued at $587,000 after buying an additional 24,777 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Bicara Therapeutics by 27.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 29,138 shares of the company’s stock valued at $508,000 after buying an additional 6,279 shares during the last quarter.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $12.06 on Tuesday. The firm has a market cap of $657.99 million and a PE ratio of -3.80. The company’s 50 day simple moving average is $10.94 and its 200-day simple moving average is $11.83. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.04. As a group, equities research analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.